Trial Profile
A study to evaluate the effectiveness and safety of changing from onabotulinum toxin A to abobotulinum toxin A in patients with focal hyperkinesias
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Mar 2022
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Muscle spasticity
- Focus Therapeutic Use
- 22 Aug 2015 New trial record
- 18 Jun 2015 Results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.